Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002107
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Phase I Study of Subcutaneously Administered Proleukin Aldesleukin in HIV-Infected Patients
Sponsor:
Chiron Corporation
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase I Study of Subcutaneously Administered Proleukin Aldesleukin in HIV-Infected Patients
Status:
COMPLETED
Status Verified Date:
1995-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the MTD and dose-limiting toxicities of recombinant interleukin-2 aldesleukin Proleukin administered subcutaneously in HIV-seropositive patients To identify a tolerable subcutaneous regimen that will replicate the immunologic improvement demonstrated in the outpatient polyethylene glycolated IL-2 and high-dose continuous infusion IL-2 studies To evaluate the incidence and level of anti-IL-2 antibody formation to subcutaneously administered Proleukin in this patient population
Detailed Description:
Patients will receive subcutaneous Proleukin and the MTD will be determined
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CS-L293-09 | None | None | None |